Objective:

To highlight recent advances in the discovery of small molecule lead compounds as potential anti-cancer agents and their mechanisms of action, particularly in overcoming drug resistance.

Key Findings:

• Parthenolide (PTL) modulates amino acid metabolism and oxidative stress in lung adenocarcinoma, targeting GCTG, which may pave the way for new therapeutic strategies.
• Wogonin shows therapeutic potential against prolactinoma by inhibiting the PI3K/AKT pathway and enhancing sensitivity to bromocriptine, indicating its role as a multi-target agent.
• Drug resistance in breast cancer is a significant challenge, with emerging targets for overcoming resistance highlighted, emphasizing the need for innovative therapeutic strategies.
• Two novel VEGFR-2 inhibitors were identified as promising candidates for papillary thyroid carcinoma, suggesting new avenues for targeted therapy.
• Lorlatinib shows potential for repurposing against a broader range of ALK mutations, which could expand treatment options for ALK-positive tumors.
• Radotinib and alectinib may provide cost-effective alternatives for targeting MEK1 in cancer therapy, addressing toxicity and resistance issues.
• Predictive 3D-QSAR models for chalcone derivatives indicate potential in treating chemoresistant ovarian cancer, highlighting the importance of computational approaches in drug discovery.
• Steroidal saponins (SSs) have anticancer effects but face challenges in clinical translation, necessitating further research to enhance their therapeutic viability.

Interpretation:

The findings collectively underscore the potential of natural products and computational approaches in identifying novel anti-cancer therapies and targets, highlighting their role in addressing drug resistance.

Limitations:

• Clinical translation of findings is limited by challenges such as low bioavailability and systemic toxicity of some compounds, necessitating innovative delivery methods.
• Experimental validation is needed for several identified compounds to confirm their clinical potential, with ongoing research aimed at addressing these gaps.

Conclusion:

The editorial emphasizes the importance of small molecule lead compounds in advancing cancer therapy and the need for continued research in this area, particularly in overcoming the limitations identified.